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luctuations in extracellular free ionized calcium concentrations ([Ca 2ϩ ] o ) accompany bone remodeling and contribute to systemic free ionized calcium (Ca 2ϩ o ) homeostasis (1) . In tissue culture models, elevations in [Ca 2ϩ ] o increase osteoblast chemotaxis and proliferation (2, 3) and alter the levels of expression of some differentiation markers (4, 5) . During mineralization, decreases in [Ca 2ϩ ] o are also likely to occur (6) , but the effect of lowering [Ca 2ϩ ] o in bone cells has not been extensively addressed. The mechanism of [Ca 2ϩ ] o -sensing by osteoblasts is unclear. The parathyroid extracellular calcium-sensing receptor (CaR) is a key player in the maintenance of a constant systemic [Ca 2ϩ ] o , predominantly through regulation of parathyroid hormone (PTH) secretion and urinary calcium excretion (7, 8) . CaR is also present in osteoblasts (9 and references therein), where a functional role is currently debated. Recently two studies have shown that CaRdeficient mice exhibit an essentially normal skeletal phenotype when the hyperparathyroidism resulting from the lack of the parathyroid CaR is prevented (10, 11) . Thus, it remains unclear whether the osteoblast CaR is a true regulator of bone function or whether its expression is vestigial (12) .
In this study, we investigated the effects of both decreasing and increasing [Ca 2ϩ ] o on osteoblast proliferation and intracellular signaling events, the expression of several osteoblast differentiation markers [core binding factor ␣1 (Cbfa1, also termed Runx2 and Osf2), osteocalcin (OC), osteopontin (OP), and type I collagen (collaI)], the activity of alkaline phosphatase (AlP), and mineralized nodule formation in the absence of systemic calciotropic factors, namely PTH and vitamin D. We further investigated the role played by the CaR in these events using an alternative, nonpermeant CaR agonist, gadolinium (Gd 3ϩ ) and a CaR inhibitor, NPS 89636 (a ''calcilytic''). We used well characterized osteoblast models, freshly isolated fetal rat calvarial cells (FRC) (13) and the clonal murine osteoblast cell line, 2T3 cells (14) . The expression of CaR in freshly frozen sections of rat and human bone was also determined.
Materials and Methods
Animals. Sprague-Dawley rats (Charles River Breeding Laboratories) were killed by cervical dislocation and used in accordance to the U.K. Animals Scientific Procedures Act of 1986.
Cell Culture. FRC cells were isolated and cultured as described (15) . The treatment media contained increasing concentrations of Ca 2ϩ o (CaCl 2 , 0.5-3 mM) or Gd 3ϩ (GdCl 3 , 10-100 M; both from Sigma-Aldrich) with or without NPS 89636 (NPS Pharmaceuticals, Toronto). Treatments were initiated 24 h after seeding and lasted for the duration of the experiments, in the presence of 100 g͞ml ascorbic acid and 3 mM ␤-glycerophosphate (both from Sigma) from confluence.
Mouse osteoblast 2T3 cells (a kind gift from Stephen Harris, University of Missouri, Kansas City) have been characterized (14) . 2T3 cells stably transfected with a 2.3-kb portion of the collaI promoter driving GFP expression (also a gift from Stephen Harris) were cultured as described (15) .
RNA Extraction. Total RNA from FRC cells was extracted and shown to be pure and intact as described (16) .
Expression of CaR Transcripts in FRC Cells. Random hexamer-primed first-strand cDNAs were prepared from 500 ng of FRC, 2T3, and rat kidney total RNAs and reverse-transcribed by using avian myeloblastosis virus-reverse transcription enzyme (Roche Molecular Biochemicals). Genomic DNA contamination was removed by using a RQ1 DNase kit (Promega). PCR amplification was performed by using oligonucleotide primers designed to amplify a 480-bp product from the mouse 2T3 cells (sense, 5Ј-AGAAGT-TCCGAGAGGAAGCC-3Ј; antisense, 5Ј-ACCTGTTGCCGC-CTTCTTCG-3Ј) and two different sets of primers to amplify 383-bp (sense, 5Ј-ACCTTTACCTGTCCCCTGAA-3Ј; antisense, 5Ј-GGGCAACAAAACTCAAGGTG-3Ј) and 545-bp (sense, 5Ј-ACCTGCTTACCCGGAAGAGG-3Ј; antisense, 5Ј-GTG-AGAGCGATTCCAAAGGG-3Ј) fragments in the extracellular region of the CaR, designed to span two and four introns, respectively, in the FRC cells. The products were sequenced with an ABI This paper was submitted directly (Track II) to the PNAS office.
Abbreviations: Ca 2ϩ o, extracellular free ionized calcium; [Ca 2ϩ ]o, extracellular free ionized calcium concentration; CaR, extracellular calcium-sensing receptor; FRC, fetal rat calvarial; Cbfa1, core binding factor ␣1; OC, osteocalcin; OP, osteopontin; AlP, alkaline phosphatase; collaI, type I collagen; PTH, parathyroid hormone; ERK1͞2, extracellular signal-regulated kinases 1 and 2; GSK3␤, glycogen synthase kinase 3␤.
Prism BigDye terminator sequencing-ready kit (Applied Biosystems), by using Amplitaq DNA polymerase and an ABI 373 DNA Sequencer.
Northern Blotting. Northern blotting of total RNA (15 g) was performed at high stringency as described (16) . The following probes used in this study were produced by RT-PCR and were rat OC, mouse collaI, mouse Cbfa1, human OP, and the housekeeping gene rat ␤-actin (17, 18) .
CaR Immunoblotting and Immunofluorescence. Crude membrane fractions were isolated from FRC cells, 2T3 cells, and rat kidney as described (19) , and SDS͞PAGE immunoblotting was performed as described (20) . For immunofluorescence, the cells were grown on glass coverslips and stained as described (19) .
CaR Immunocytochemistry. The rat femurs and kidneys were aseptically dissected and snap frozen for 60 sec at Ϫ170°C in isopentane. The samples of human mandibles were neck resections from patients with squamous cell carcinoma invading bone and were taken after ethical approval and signed informed consent.
Frozen samples were embedded and sectioned as described (21) . The sections were fixed in 10% buffered formalin (Sigma-Aldrich; 3-5 min), blocked with Seablock (Perbio Science, Tattenhall, U.K.; 30 min), and incubated with affinity-purified rabbit anti-CaR polyclonal antibodies (1:100 in 0.2% BSA in PBS) or primary antibodies preabsorbed with an excess of antigenic peptide. Secondary antibodies [FITC-conjugated swine anti-rabbit immunoglobulins 1:50 in PBS (Molecular Probes)] were applied for 30 min. Between all steps, the sections were washed in PBS only or 0.2% BSA in PBS. They were mounted in an antifade mounting medium (Perbio Science).
For EDTA-decalcified paraffin wax histology, the femurs were prepared, and the immunoperoxidase experiments were performed as described (22) by using affinity-purified CaR polyclonal primary antibodies (1:100) alongside a peptide block negative control as above. The sections were counterstained in hematoxylin. All experiments were repeated on sections from at least three tissue samples. The images were prepared by using a Zeiss Axioplan microscope with a manual photographic camera and Agfa RS50 color film or acquired digitally by using a Zeiss Axiocam system. Confocal microscopy was performed as described (19) by using undecalcified sections (30 m) permeabilized in 0.075% saponin in PBS.
Intracellular Signaling in FRC and 2T3 Cells. The experiments were performed as described (19) with minor modifications. Briefly, the cells were equilibrated in the experimental buffer (20 min, 0.5 mM Ca ) and lysed. The effects of antagonists were ascertained by pretreating the cells before the stimulation step (5 min for mitogen-activated protein kinase kinase inhibitor PD98059 and phosphatidylinositol 3-kinase inhibitors wortmannin and LY294002, 3 min for CaR inhibitor NPS 89636) followed by the cotreatment with the agonist.
Relative changes in phosphorylation of extracellular signalregulated kinases 1 and 2 (ERK1͞2) mitogen-activated protein kinases, Akt, and GSK3␤ were measured by semiquantitative Western blotting by using affinity-purified antibodies raised against the specific dual phosphopeptide sequences of ERK1͞2 (Promega) and antibodies raised against the Akt and GSK3␤ phosphopeptide sequences (Cell Signaling, Beverly, MA). As a control, a non-phospho-specific antibody recognizing ERK1͞2 mitogen-activated protein kinase was used to assess total ERK levels.
Proliferation Assay. The cells were plated in 24-well plates (5,000 cells per cm 2 ) and, after treatment, trypsinized and counted three times with a Coulter Counter (Beckman Coulter). In addition they were assayed in 96-well plates for proliferating activity by the BrdUrd incorporation assay according to the manufacturer's instructions (Roche Diagnostics). ]. The GFP levels were assessed in 0.05% Triton X-100 freeze-thawed lysates by measuring fluorescence emission levels at excitation of 488 nm by using a 520-nm long-pass emission filter (Wallac Victor 2 1420 multilabel counter, Perkin-Elmer).
AlP Activity. The AlP activity was assayed by colorimetry as described (23).
Von Kossa Staining. Von Kossa staining was performed as described (24) . The images of mineralized nodules were captured on a flatbed scanner and image analysis software (SCION, Frederick, MD) was used to count the number of and total area of the mineralized nodules.
Statistical Analysis. The statistical significance was assessed by one-way ANOVA with Tukey's post hoc test or Student's t test. Observations were considered to be significantly different for P Ͻ 0.05.
Results and Discussion
Bone formation is characterized by a distinctive sequence of events beginning with the commitment of mesenchymal cells to osteoblast lineage, followed by osteoblast proliferation, growth, and differentiation, culminating in the formation of a mineralized extracellular matrix by terminally differentiated osteoblasts (25) . Fluctuations in systemic [Ca 2ϩ ] o may influence these processes by inducing changes in circulating levels of PTH and 1,25(OH) 2 -vitamin D 3 . However, it is currently unclear whether changes in [Ca 2ϩ ] o can directly affect bone cell function independently of their effects on circulating calciotropic factors. The aim of this study was to investigate the direct effects of acute (minutes), medium-term (hours), and chronic (days to weeks) changes in [Ca 2ϩ ] o on osteoblast models of freshly isolated FRC cells and the clonal osteoblast cell line 2T3 and, furthermore, to investigate the involvement of the CaR in these responses.
CaR Is Expressed in Osteoblasts in Vitro and in Vivo. The expression of CaR transcripts (Fig. 1A) and protein ( Fig. 1 B and C) in rat (FRC) and murine osteoblast clonal (2T3) cell lines was confirmed by RT-PCR using intron-spanning primers and by immunoblotting, respectively. The PCR products were sequenced and shown to be identical to the rat and mouse kidney CaRs, respectively.
We confirmed the presence of CaR-specific (i.e., peptideprotectable) immunofluorescence in the cells of osteoblastic lineage in decalcified rat femur preparations ( Fig. 2A) . We also provide evidence for CaR expression in freshly frozen undecalcified rat ( Fig. 2 B and C) and human bone (Fig. 2D ). Osteoblast and osteocyte staining is evident in both decalcified (Fig. 2 A) and undecalcified freshly frozen ( Fig. 2 B and C) rat femur preparations. At higher magnifications we observed differential immunoreactivity in the osteocyte populations, possibly related to various maturation stages of the osteocytes (Fig. 2C) . Confocal microscopy confirmed a plasma membrane distribution (Fig. 2C Inset) . This distribution pattern was confirmed in the human mandible (Fig. 2D) .
Osteoblast Models Respond to [Ca 2؉ ]o by Intracellular Signaling
Events. Increasing [Ca 2ϩ ] o stimulates proliferation and migration of osteoblasts through the mitogen-activated protein kinase͞ ERK pathway (26, 27 ] o or Gd 3ϩ treatment stimulated the serine͞threonine kinase Akt, as evident from the phosphorylation of its activation sites (Thr-308 and Ser-473), as well as phosphorylation of GSK3␤ on its inhibitory site (Ser-9; Fig. 3A ). These signals are associated with proliferative (ERK) and antiapoptotic (Akt, GSK3␤) responses. Gd 3ϩ -induced ERK1͞2 activation was both time- (Fig. 3Bi ) and concentration- (Fig. 3Bii) dependent, was abolished by inhibition of mitogenactivated protein kinase kinase 1 (with PD98059), and was in part attenuated by inhibition of phosphatidylinositol 3-kinase (with two structurally unrelated compounds, wortmannin and LY294002; Fig. 3C ). The Ca 2ϩ o and Gd 3ϩ responses were significantly reduced by the CaR antagonist NPS 89636 (Fig. 3D) . was associated with a concentration-and time-dependent mitogenic response (Fig. 4) . Elevations in [Ca 2ϩ ] o from 1.2 to 1.8 or 2.5 mM were sufficient to elicit proliferation after chronic treatments of at least 7 days. Lowering the [Ca 2ϩ ] o to 0.5 mM decreased FRC cell proliferation (Fig. 4A Upper) . The reduced cell number resulted in part from increased cell death (approximately 9 times more induced FRC cell proliferation after 14 days of treatment, whereas the 50 M dose increased proliferation after 5 days of treatment (Fig. 4B Upper) . In addition, after 10 days of treatment, BrdUrd incorporation in FRC cells was greater in the presence of 2.5 mM Ca ] o promote differentiation of FRC cells, as evident from the up-regulation in the mRNA expression levels of osteoblast markers at early and late stages of differentiation (Fig.  5) . Doubling of the normal [Ca 2ϩ ] o to 2.5 mM increased the promoter activity (Fig. 5A) as well as mRNA expression levels (by 10%; Fig. 5B ) of collaI, the major structural component of the organic matrix. This increase was maximal 24 h after the Ca 2ϩ o treatment and subsided at later time points (not shown), consistent with an early role of collaI in the osteoblast maturation sequence. A notable finding is the up-regulation of mRNA levels for Cbfa1, the master osteoblast transcription factor responsible for osteoblast differentiation and mineralization (ref. 28 and Fig. 5C ). Transcription of OC and OP, the major osteoblast proteins downstream of Cbfa1, were also induced by increasing [Ca 2ϩ ] o . This effect was differentiation-stage specific, beginning after 7 days and at its most marked after 12 days of treatment, which coincides with the commencement of nodule formation. This is evident for both the 1.8 mM treatment (ϩ87% for Cbfa1, ϩ146% for OC, and ϩ115% for OP) and the 2.5 mM treatment (ϩ75% for Cbfa1, ϩ168% for OC, and ϩ82% for OP; Fig. 5C ). This effect was sustained during ] o on Cbfa1, OC, and OP (ϩ82% for Cbfa1 and ϩ145% for OC after 12 days and ϩ115% for OP after 7 days; Fig.  5C ), but not collaI mRNA expression levels. Treatments with various [Ca 2ϩ ] o or [Gd 3ϩ ] did not alter the mRNA expression of bone morphogenetic protein 2 (data not shown) or of the housekeeping gene ␤-actin (Fig. 5C ). 2؉ ]o-Dependent. AlP has important functions during crystal formation (29) . We found that its optimal enzymatic activity depends on maintaining [Ca 2ϩ ] o within a narrow (1.2-1.8 mM) range (Fig. 6A) , and that small deviations inhibit its activity. A recent study identified a Ca 2ϩ binding site in the tissue nonspecific AlP protein (the predominantly expressed isoform in bone), the mutation of which results in a severe phenotype, indicating that calcium is fundamental to the AlP activity (29) . Our experiments support these observations and raise the question of the interplay between AlP function and Ca ] o directly stimulated the production of mineralized bone nodules by FRC cells, in the absence of systemic calciotropic factors (Fig. 7A) . The steepness of the sigmoidal curve that fits the relationship between mineralized nodule formation (area and number of nodules) and [Ca 2ϩ ] o and its EC 50 of Ϸ1.1 mM (Fig. 7A) indicates that relatively small deviations in Ca 2ϩ o from the physiological range exert a significant impact on mineralization. This effect is reminiscent of the CaR-regulated PTH secretion from the parathyroid glands, where the [Ca 2ϩ ] o necessary to produce 50% inhibition of PTH secretion is 1.2 mM (30). The increased mineralization in the presence of 1.8 mM Ca o was reduced by the CaR antagonist NPS 89636 (number of nodules by Ϫ27 Ϯ 7% and area of nodules by Ϫ27 Ϯ 3.5%; n ϭ 3, P Ͻ 0.01 for both; Fig. 7C ).
AlP Activity in FRC Cells Is [Ca
Inhibitory effects of high [Ca 2ϩ ] o on osteoblast AlP activity and release have been reported (31, 32) . Furthermore, the loss of AlP activity has been correlated with the accumulation of calcium in matrix vesicles, which are involved in the process of mineralization (23) . Nevertheless, the concomitant increase in mineralization with a decrease in AlP activity in the presence of elevated [Ca 2ϩ ] o has not been previously observed. We speculate that in hypercalcemic conditions AlP may be involved in inhibition of excessive and͞or dystrophic mineralization.
Mineralization is regulated by a complex arrangement of stimulatory and inhibitory components (33, 34) . We observed a concentration-dependent increase in collaI, Cbfa1, OC, and OP mRNAs and a decrease in the activity of AlP in response to relatively small elevations in [Ca 2ϩ ] o . We hypothesize that Ca Fig. 5C ). The significance of these findings requires further investigations.
Is the CaR Involved in Ca 2؉ o -Sensing by Osteoblasts? The CaR expression in osteoblasts has been reported (9) . We have confirmed these findings in decalcified sections, established the presence of CaR transcripts in freshly isolated osteoblasts and in an osteoblastderived clonal cell line, and demonstrated the presence of the CaR in freshly frozen bone. It has been reported that the osteoblast CaR exhibits a different pharmacological profile from that of parathyroid cells, e.g., in its response to Mg 2ϩ , and that therefore the osteoblast and parathyroid CaRs are distinct (35) . The portions of the FRC and 2T3 CaR amplified, sequenced, and confirmed to be homologous to the kidney CaR in this study constitute the Ca 2ϩ binding site (36) . Although sequence differences could arise in the transmembrane region of the osteoblast CaR, which also binds triand polyvalent cations, the functional discrepancies between the parathyroid and the osteoblast CaRs cannot be explained simply on the basis of putative structural differences. G protein-coupled receptors exhibit ''conditional efficacy,'' the ability to change their behavior toward the host cell in a way that ligand structure manipulates both the extent and the quality of efficacy of an agonist increased AlP activity in FRC cells after 2 days of treatment (n ϭ 6; P Ͻ 0.05 for 25 and 100 M and P Ͻ 0.001 for 50 M). However, this effect was transient, and, after 3 days, 100 M Gd 3ϩ decreased the enzyme activity. No differences were observed after 18 days of treatment. The significant differences with regard to the control are marked by asterisks ( * , P Ͻ 0.05; ** , P Ͻ 0.01; *** , P Ͻ 0.001).
(37). This ability could account for the observed pharmacological differences of the CaR in bone and in other cell types.
Our most striking finding is the narrow range of osteoblast sensitivity to [Ca 2ϩ ] o . During bone resorption, in the sealed compartment between the osteoclast resorbing surface and the mineral surface, up to 40 mM Ca 2ϩ o can accumulate (38) . Nevertheless, a resorbing osteoclast releases Ͻ2 mM Ca 2ϩ from the nonresorbing surface, a concentration that plateaus after 3 h of activity (39) . These findings indicate that the [Ca 2ϩ ] o that osteoblasts are exposed to in vivo are likely to be an order of magnitude smaller than the commonly thought 8-40 mM. This range of sensitivity in osteoblasts overlaps with the activation range for the parathyroid CaR and the one observed here.
To dissociate the extracellular and intracellular effects of elevating the [Ca 2ϩ ] o on osteoblast function, we confirmed that an alternative CaR agonist, Gd 3ϩ , mimics, whereas the CaR antagonist, NPS 89636, blocks most of the effects of increasing [Ca 2ϩ ] o . Non-CaR osteoblast mechanisms have been suggested (35) , for instance, certain metabotropic glutamate receptors that are present in bone (40) and can be activated both by Ca 2ϩ o and by Gd 3ϩ (41) . Nevertheless, the Ca 2ϩ o -and Gd 3ϩ -sensitive subtype metabotropic glutamate receptor 1␣ is not expressed in osteoblasts (42) . In addition, the concentrations of Ca 2ϩ o and Gd 3ϩ required to evoke metabotropic glutamate receptor 1␣ responses are considerably higher than those used here (41) . Taking these results together, the simplest interpretation of the current data is that osteoblasts express a functional CaR that plays a fundamental role in various aspects of their function.
In conclusion, we show that osteoblasts sense and respond to Ca 
